The term Rivaroxaban market, therefore, means the movement, sale, and application of Rivaroxaban, a drug that is taken orally to forestall the formation of blood clots in cases like DVT, PE, and stroke in those with AFib. Thus, certain compounds such as Rivaroxaban acting directly by inhibiting factor Xa are valuable in not only the acute but also chronic treatment of thromboembolic disorders because they decrease the risk of recurrent thrombotic events. It has been more embraced in many health care facilities as an oral therapy compared to other anticoagulants such as warfarin.

Serotonin Norepinephrine Inhibitor Market Size Was Valued at USD 6.30 Billion in 2023, and is Projected to Reach USD 9.36 Billion by 2032, Growing at a CAGR of 4.50% From 2024-2032.

Self-Testing Market Size Was Valued at USD 10.54 Billion in 2023, and is Projected to Reach USD 17.21 Billion by 2032, Growing at a CAGR of 5.60% From 2024-2032.